Inventiva S.A. American Depository Shares (IVA)
IVA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/0001104659-26-040704-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IVA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | 2020 |
| SEC CIK | 0001756594 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | France |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.0M |
| Net income | -$391.4M |
| Operating income | -$155.8M |
| Net margin | -7899.6% |
| Operating margin | -3145.5% |
| Revenue growth | -51.9% |
| Cash | $109.8M |
| Total assets | $275.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 158.3× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding our ability to continue as a going concern." | 20-F 2026-04-08 |
| Cash and burn | $109.8M cash; operating cash flow -$29.0M a quarter. | Report 2025-12-31 |
| Shares outstanding | 193,236,978 (2025-12-31); 95,662,391 a year earlier; 42,134,169 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG SA, Paris La Défense, France | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $5.0M | -$391.4M | -$115.9M | $109.8M | $66.2M | $5.0M | 20-F 2026-04-08 |
| FY 2021 2021-12-31 | Not filed | -$49.6M | Not filed | Not filed | No debt tags | Needs four quarters | 20-F 2022-03-11 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-02 |
| Latest annual report | 20-F | 2026-04-08 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-06 |
Source: SEC EDGAR submissions feed, 228 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.2% |
| 1 month | +28.2% |
| 3 months | -20.0% |
| Year to date | -20.9% |
| 1 year | -3.7% |
| From 52-week high | -48.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| ARDX | Ardelyx Inc. | $3.07 | -0.65% | $771.7M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| OBX | Obsidian Therapeutics Inc. | $12.36 | -1.59% | $763.5M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier